2023-04-18 09:50:51 ET
- Dyadic International ( NASDAQ: DYAI ) stock rose ~6% on Tuesday after the company said it received a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for an application covering claims for developing and making seasonal and pandemic influenza vaccines from its C1 protein production platform.
- The patent application No. 16/640,483 is titled 'Production Of Flu Vaccine In Myceliophthora Thermophila' and is expected to provide patent protection through 2038.
- "We believe C1 has the potential to become a global solution for seasonal or pandemic rapid production, at affordable costs for developed and emerging countries, and for mono or multi-valent vaccines," said Dyadic CEO Mark Emalfarb.
For further details see:
Dyadic stock rises on upcoming US patent linked to flu vaccine platform